Company: TVRD
Filing Date: 2025-11-13
Form Type: 424B3
Source: 0001104659-25-111336
Chunk: 171

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-11-13
Form: 424B3
Chunk 171
---
 cause the market price of Tvardi’s
common stock to fluctuate include:

​

| ● | the ability of Tvardi to obtain regulatory approvals for its product candidates, and delays or failures to obtain such approvals (such as Tvardi’s announcement regarding its Phase 2 trial of TTI-101 in IPF in October 2025); |

| ● | failure of any of Tvardi’s product candidates, if approved, to achieve commercial success; |

| ● | failure by Tvardi to maintain its existing third-party license and supply agreements; |

| ● | failure by Tvardi or its licensors to prosecute, maintain, or enforce its intellectual property rights; |

| ● | changes in laws or regulations applicable to Tvardi’s product candidates; |

| ● | any inability to obtain adequate supply of Tvardi’s product candidates or the inability to do so at acceptable prices; |

| ● | adverse regulatory authority decisions; |

| ● | introduction of new products, services or technologies by Tvardi’s competitors; |

| ● | failure to meet or exceed financial and development projections Tvardi may provide to the public; |

| ● | failure to meet or exceed the financial and development projections of the investment community; |

| ● | the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; |

| ● | announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by Tvardi or its competitors; |

| ● | disputes or other developments relating to proprietary rights, including patents, litigation matters, and Tvardi’s ability to obtain patent protection for its technologies; |

| ● | additions or departures of key personnel; |

| ● | significant lawsuits, including patent or stockholder litigation; |

| ● | if securities or industry analysts do not publish research or reports about Tvardi’s business, or if they issue an adverse or misleading opinion regarding its business and stock; |

<div align='center'>101</div>

Table of Contents

| ● | changes in the market valuations of similar companies; |

| ● | general market or macroeconomic conditions; |

| ● | sales of its common stock by Tvardi or its stockholders in the future; |

| ● | trading volume of Tvardi’s common stock; |

| ● | failure to maintain compliance with the listing requirements of The Nasdaq Capital Market; |

| ● | announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant